Vol. 2 No. 2 (2023): Vol 2 Issue 2 2023

Articles

• Antibody-Drug Conjugate Payload Chemistry and Off-Target Toxicity: Mapping Class Effects to Organ Systems

  Iveta Hejtmanek, Lukas Grigaliunas, Anouck Origer (Author)

  55-63

  • pdf

• Radioligand Therapy Beyond Neuroendocrine Tumours: Dosimetry, Supply Chain and Access

  Ben Kirsch-Wag, Stanislav Slavkovsky, Estibaliz Alcantud (Author)

  64-73

  • pdf

• PROTAC Degraders in Early Development: Hook Effects, Selectivity and What Reaches the Clinic

  Petra Skoric, Alexandra Tanasescu, Adrien Cazalet (Author)

  74-82

  • pdf

• Faecal Microbiota Transplantation for Recurrent Infection: Donor Screening and Product Standardisation

  Martin Kirov-Ganev, Aada Kettunen, Gustaf Wickstrom (Author)

  83-91

  • pdf

• Adaptive Licensing and Conditional Approval: A Perspective on Evidence Owed After Market Entry

  Oceane Chastenet, Sorcha Crotty, Austeja Rimkute (Author)

  92-100

  • pdf

• Severe Delayed Hypersensitivity to a Novel Kinase Inhibitor: A Case Report With Rechallenge Data

  Marloes Wiegersma, Laine Bergmanis, Weronika Kaczmarczyk (Author)

  101-109

  • pdf

• Circulating Tumour DNA for Minimal Residual Disease: Assay Sensitivity and the Decisions It Cannot Yet Support

  Theresa Wiesinger, Lennart Bruggemann, Radu Sandulescu (Author)

  110-119

  • pdf